

26th Annual Alzheimer Day

Current Clinical Trials at the Mesulam Center

Brittanie Muse, MSPH; Alexis Menias; Robert Shepard; Emily Rogalski, PhD; Sandra Weintraub, PhD;
Daniel Lee, MD; Joshua Cahan, MD; Ian Grant, MD

Northwestern University Mesulam Center for Cognitive Neurology & Alzheimer's Disease

brittanie.muse@northwestern.edu

Current Clinical Trials at the Mesulam Center

The treatment of Alzheimer's disease (AD) and related dementias is a central aim for the Mesulam Center for Cognitive Neurology and Alzheimer's Disease. The Mesulam Center is collaborating with the Alzheimer's Therapeutic Research Institute (ATRI) and the Alzheimer's Disease Cooperative Study (ADCS) in clinical trials and observational studies for individuals with AD and other forms of dementia.

Emerging clinical trials and research studies are reviewed and approved by the Executive Committee of the Mesulam Center. Recruitment sources for potentially eligible participants include referrals from the Clinical Core of the Mesulam Center, Northwestern Medicine Enterprise Data Warehouse (NMEDW), and various research registries (e.g., Illinois Women's Health Registry, TrialMatch, ResearchMatch, etc.) as well as advertisements and educational events in the Chicago area community. Recruitment efforts have continued to emphasize the inclusion of participants from minority groups and otherwise underserved communities.

Current trials open for recruitment:

- 1) Memory Improvement through Nicotine Dosing (MIND): The MIND study will determine if a daily nicotine patch is able to produce a significant cognitive, clinical, and functional improvement in participants with memory complaints or participants diagnosed with Mild Cognitive Impairment (MCI). Neuronal nicotinic receptors have long been known to play a critical role in memory function, attention, and learning. Participants enrolled in this study received either the nicotine patch, titrated to 21mg/day, or a placebo skin patch. **This treatment trial is still recruiting and expected to be completed in 2021.**
- 2) Alzheimer's Disease Neuroimaging Initiative – 3 (ADNI3): The ADNI3 study is designed to identify biomarkers that may be useful in the diagnosis of early AD. The ADNI3 study will use annual cognitive assessments, blood and cerebrospinal fluid samples, MRI, and PET scans to evaluate biomarkers that may be useful in disease prediction. **This observational trial is still recruiting and expected to be completed in 2022.**

3) Longitudinal Early-onset Alzheimer's Disease Study (LEADS): The LEADS study examines disease progression in adults with early-onset Alzheimer's disease. Both, cognitively normal and cognitively impaired participants undergo longitudinal clinical and cognitive assessments, biomarker and genetic tests, brain imaging scans (including PET and MRI), and cerebral spinal fluid collection. Researchers will compare data between cognitively normal participants and late-onset AD participants to study different elements of disease progression. **This observational trial is still recruiting and expected to be completed in 2022.**

Current trials no longer recruiting:

1) Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study: The A4 study is a prevention trial aimed at treating amyloid-positive but otherwise healthy individuals (aged 65-85) at risk for developing Alzheimer's disease (AD). Cognitively-normal individuals were screened for amyloid burden in their brains (via PET scan). Those with positive amyloid PET scans were enrolled into the study and are currently being treated with an anti-amyloid antibody (Solanezumab) or placebo. **This treatment trial is no longer recruiting and is expected to be completed in 2022.**

2) Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN): The goal of this trial is to evaluate the rate of cognitive change in individuals without an amyloid burden (i.e., amyloid-negative PET scans). This observational study runs in parallel to the A4 Study, and there is no drug treatment. **This observational trial is no longer recruiting and expected to be completed in 2022.**

3) T2 Protect AD (T2): The T2 Protect AD tests the investigational drug, troriluzole, in people with mild to moderate Alzheimer's disease. The study is designed to determine whether troriluzole can protect against, slow down, and/or potentially improve memory and thinking problems associated with AD progression. **This treatment trial is no longer recruiting expected to be completed in 2020.**

To learn more about participating in our currently recruiting trials (MIND, ADNI3, and LEADS) please email clinicaltrials.mesulam@northwestern.edu or call (312) 503-5674.

This research was presented as part of the 26th Annual Alzheimer Day hosted by the Northwestern University Mesulam Center for Cognitive Neurology and Alzheimer Disease on September 24, 2020.

brain.northwestern.edu